Sugi Predict

Sugi Predict / Compounds / SCHEMBL29542708

SCHEMBL29542708

SCHEMBL29542708

CSCC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CCN)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 12/20 0.66
▸ MC4R P32245 1/20 0.61
▸ MC5R P33032 1/20 0.61
▸ MC3R P41968 1/20 0.61
▸ MC1R Q01726 1/20 0.61
▸ GLP1R P43220 4/20 0.61
▸ GCGR P47871 3/20 0.61
▸ NPY1R P25929 1/20 0.61
▸ NPY2R P49146 1/20 0.61
▸ NPY4R P50391 1/20 0.61
▸ NPY5R Q15761 1/20 0.61
▸ CXCL8 P10145 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30567307 0.88 NPY1R (0.67) CXCR4GLP1RGCGRNPY1RNPY2R
SCHEMBL31182642 0.87 NPY1R (0.73) CXCR4GLP1RGCGRNPY1RNPY2R
SCHEMBL30804655 0.87 CXCR4 (0.66) CXCR4GLP1RGCGRNPY1RNPY2R
SCHEMBL30640750 0.87 CXCR4 (0.69) CXCR4MC4RMC5RMC3RMC1R
SCHEMBL31000409 0.86 CXCR4 (0.71) CXCR4GLP1RGCGRNPY1RNPY2R
SCHEMBL29372759 0.86 NPY2R (0.72) CXCR4GLP1RNPY1RNPY2RNPY4R
SCHEMBL30495698 0.86 GLP1R (0.66) CXCR4GLP1RGCGRNPY1RNPY2R
SCHEMBL31000406 0.86 CXCR4 (0.70) CXCR4GLP1RGCGRNPY1RNPY2R
SCHEMBL30553763 0.86 KISS1R (0.59) CXCR4MC4RMC5RMC3RMC1R
SCHEMBL30423138 0.85 CXCR4 (0.69) CXCR4NPY1RNPY2RNPY4RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3875113-B1 TRANSMEMBRANE DOMAIN DERIVED FROM HUMAN LRRC24 PROTEIN KOREA RES INST CHEMICAL TECH (KR) 2026-04-22 — — EP disclosed
EP-4713444-A2 FUSION PROTEINS COMPRISING CAS ENZYMES AND DNA-BINDING PROTEINS Sarepta Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
EP-3359685-B1 MODULATION OF GENE EXPRESSION FOR DEREGULATED PROTEIN EXPRESSION UNIV SOUTHAMPTON (GB) 2026-01-28 — — EP disclosed
US-20250257359-A1 MUSK-TARGETING OLIGONUCLEOTIDES BOLDEN THERAPEUTICS, INC. 2025-08-14 — — US disclosed
EP-4591931-A2 MUC5B-TARGETED ANTISENSE OLIGONUCLEOTIDES AND RELATED METHODS FOR MODULATING MUCIN EXPRESSION Splisense Ltd. (IL) 2025-07-30 — — EP disclosed
US-20250027054-A1 Compositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell Types Elixirgen Scientific, Inc (US) 2025-01-23 — — US disclosed
US-12202876-B2 Transmembrane domain derived from human LRRC24 protein KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-01-21 — — US disclosed
US-20240409930-A1 MUC5B-TARGETED ANTISENSE OLIGONUCLEOTIDES AND RELATED METHODS FOR MODULATING MUCIN EXPRESSION SPLISENSE LTD. (IL) 2024-12-12 — — US disclosed
EP-4466360-A1 MUSK-TARGETING OLIGONUCLEOTIDES Bolden Therapeutics, Inc. (US) 2024-11-27 — — EP disclosed
WO-2024238595-A2 FUSION PROTEINS COMPRISING CAS ENZYMES AND DNA-BINDING PROTEINS SAREPTA THERAPEUTICS, INC. (US) 2024-11-21 — — WO disclosed
US-20230041359-A1 HUMAN MIRNAS FOR USE IN DIAGNOSIS, PROGNOSIS, AND THERAPY OF HUMAN CONDITIONS AND DISEASES UNIV JEFFERSON (US) 2023-02-09 — — US disclosed
US-20220364058-A1 Method For Promoting Differentiation Of Pluripotent Stem Cells By Reducing Undifferentiated State Thereof KEIO UNIVERSITY (JP) 2022-11-17 — — US disclosed
US-20220306718-A1 TRANSMEMBRANE DOMAIN DERIVED FROM HUMAN LRRC24 PROTEIN KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-09-29 — — US disclosed
US-11396644-B2 Method for promoting differentiation of pluripotent stem cells by reducing undifferentiated state thereof KEIO UNIVERSITY (JP) 2022-07-26 — — US disclosed
US-11390869-B2 Reducing intron retention UNIVERSITY OF SOUTHAMPTON (GB) 2022-07-19 — — US disclosed
WO-2022144882-A2 P21 MRNA TARGET AREAS FOR SILENCING 1E THERAPEUTICS, LTD. (IL) 2022-07-07 — — WO disclosed
WO-2022144883-A2 P21 MRNA TARGETING DNAZYMES 1E THERAPEUTICS, LTD. (IL) 2022-07-07 — — WO disclosed
EP-4015648-A1 REDUCING INTRON RETENTION University Of Southampton (GB) 2022-06-22 — — EP disclosed
EP-4008724-A1 AN AMPHIPATHIC PEPTIDE Phion Therapeutics Limited (GB) 2022-06-08 — — EP disclosed
US-11293064-B2 Human miRNAs for use in diagnosis, prognosis, and therapy of human conditions and diseases THOMAS JEFFERSON UNIVERSITY (US) 2022-04-05 — — US disclosed
Send feedback